EMEA Search Results

Newsroom

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

• Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function • Results demonstrated significant reduction of systemic lupus erythematosus disease activity which continued beyond the 24-week primary endpoint, and were sustained through Week 52 in the nipocalimab 15 mg/kg groupa • The Phase 3 study of nipocalimab is currently underway in people living with systemic lupus erythematosus – a debilitating autoantibody-driven disease which can lead to systemic organ damage

Newsroom

Johnson & Johnson’s Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the risk of developing metastasis or death1 Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine1,2

Newsroom

New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma

MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of Johnson & Johnson’s TECVAYLI® as early as second line1 TECVAYLI® delivered deep and durable responses, with nearly two-thirds of patients achieving a complete response or better2

Newsroom

IMAAVY® (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained minimal symptom expression (MSE) experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 study EPIC, a head-to-head study, will compare nipocalimab versus another FcRn blocker in generalised myasthenia gravisa

Політика використання файлів cookie

Newsroom

ICOTYDE™ (icotrokinra) one-year results demonstrate lasting skin clearance and favourable safety profile in once-daily tablet for plaque psoriasis

Johnson & Johnson presents new data showing: - High rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies. - Completely clear skin achieved at Week 52 in nearly 60% of adolescents treated with icotrokinra in the ICONIC-LEAD study.

Newsroom

New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting

Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness and tolerability in a real-world patient population, which on average had severe, chronic, treatment-resistant depression (TRD). The study offers distinct new insight into the durability of treatment effect, with symptom stability maintained across 6 months following discontinuation of esketamine NS.

Newsroom

Johnson & Johnson’s DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and innovation, continuing to transform multiple myeloma care

Newsroom

TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free survival and overall survival versus standard of care, reducing the risk of disease progression or death by 71% in a high unmet need patient population2

Newsroom

European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard of care1 Approximately one in ten patients with mHSPC harbour BRCA1/2 alterations, reinforcing the need for new targeted treatment options2 Expanded indication for niraparib and abiraterone acetate delivers a precision-based treatment approach for this patient population1

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

Search Results

No Results

EMEA Search Results